Journal of obstetrics and women's diseasesJournal of obstetrics and women's diseases1684-04611683-9366Eco-Vector301810.17816/JOWD65216-23Research ArticlePre-eclampsia. Selection of obstetric tacticsDobrokhotovaYuliya EProfessor, MD. Head of Department of Obstetrics and Gynecologypr.dobrohotova@mail.ruMakarovOleg VProfessor, MD. Department Obstetrics and Gynecologyprofmakarov@mail.ruLysyukElena YuPhD. Laboratory of Gene Therapy, Head of Laboratoryelenlys@gmail.ruOlenevAnton SPhD. Deputy chief physician of obstetricsfelidis@mail.ruKouznetsovPavel APhD, Associate Professor of the Department of Obstetrics and GynecologyPoohsmith@mail.ruDjokhadzeLela SPhD, assistant of the Department obstetrics and gynecologyanton-b1@mail.ruOsmanovaAnna Pclinical intern of the Department of Obstetrics and Gynecologyannaosmanova92@mail.ruRussian National Research Medical University named after N.I. Pirogov (RNIMU)Institute of Gene Biology, Russian Academy of SciencesPerinatal center of clinical hospital No 2415032016652162315032016Copyright © 2016, Dobrokhotova Y.E., Makarov O.V., Lysyuk E.Y., Olenev A.S., Kouznetsov P.A., Djokhadze L.S., Osmanova A.P.2016Relevance. At the present time, despite the large number of studies, the root causes of pre-eclampsia remain unknown. In recent years, attention is paid to the study of the role of vascular growth factors in the pathogenesis of various obstetric pathologies, including pre-eclampsia. The aim of our study was to examine the features of the angiogenic imbalance in determining the severity of pre-eclampsia, and further tactics of conducting pregnant women. Matherials and Methods. 135 pregnant women were examined: I group - 50 pregnant women with preeclampsia moderate; II group - 36 pregnant women with preeclampsia-severe; Group III - 49 pregnant women with physiological pregnancy. All patients special methods of investigation have been carried out - the definition of levels of pro-angiogenic (PlGF) and anti-angiogenic (sFlt-1, sEng) factors in the serum in 28-34 weeks gestation. In our study we found significant differences in the content of vascular growth factors in patients in the three comparison groups. Results. With an increase in the severity of pre-eclampsia decrease pro-angiogenic placental vascular factors to a greater extent than other vascular factors points to the aggravation of the pathological process and can be used as an additional criterion of pre-eclampsia severity. The level of vascular growth factors and their relationship with a certain probability, reflects the extent of endothelial dysfunction that predicts the best time of prolongation of pregnancy in patients with pre-eclampsia. Conclusion. Use of vascular growth factor in the diagnosis and determining the severity pre-eclampsia, along with traditional clinical and laboratory research will optimize the obstetric tactics in these patients.preeclampsiavascular growth factorsoptimization tacticsпреэклампсиясосудистые факторы ростаоптимизация тактики ведения[Богданов С.В., Волкова Э.Г., Жаворонкова Е.Ю. Гетерогенность гипертензивных состояний у беременных // Материалы 4-го Уральского съезда кардиологов: сб. материалов. - Ханты-Мансийск, 2009. - С. 23-25. [Bogdanov SV, Volkova EG, Zhavoronkova EY. Geterogennost’ gipertenzivnykh sostoyaniy u beremennykh. Materialy 4 Ural’skogo s»ezda kardiologov: sb. Materialov. Khanty-Mansiysk; 2009:23-25. (In Russ).]][Gifford RW, August PA, Cunningham G. Working Group Report on High Blood Pressure in Pregnancy. 2006:38.][Villar J, Say L, Gulmezoglu AM, et al. Eclampsia and preeclampsia: a worldwide health problem for 2000 years. In Critchley H, Maclean A, Poston L, Walker J, eds. Preeclampsia. London: RCOG; 2003.][Запорожец Э.Е., Шувалова М.П., Цымлякова Л.М., и др. Основные показатели деятельности службы охраны здоровья матери и ребенка в Российской Федерации. Статистическая форма 32 за 2012 год. Российское общество акушеров-гинекологов; ФГБУ «НЦАГИП им. В.И. Кулакова» Минздрава России; ФГБУ «ЦНИИОИЗ» Минздрава России. - М., 2013. [Zaporozhets EE, Shuvalova MP, Tsymlyakova LM, et al. Osnovnye pokazateli deyatel’nosti sluzhby okhrany zdorov’ya materi i rebenka v Rossiyskoy Federatsii. Statisticheskaya forma 32 za 2012 god. Rossiyskoe obshchestvo akusherov-ginekologov; FGBU “NTsAGIP im. V.I. Kulakova” Minzdrava Rossii; FGBU “TsNIIOIZ” Minzdrava Rossii. - Moscow; 2013. (In Russ).]][Мозговая Е.В., Малышева О.В., Иващенко Т.Э. Эндотелиальная дисфункция при гестозе. Патогенез, генетическая предрасположенность, диагностика и профилактика: метод. рекомендации. - СПб., 2003. [Mozgovaya EV, Malysheva OV, Ivashchenko TE. Endotelial’naya disfunktsiya pri gestoze. Patogenez, geneticheskaya predraspolozhennost’, diagnostika i profilaktika: metod. rekomendatsii. Saint Petersburg; 2003. (In Russ).]][Чулков В.С. Особенности течения и исходов беременности у женщин с различными формами артериальной гипертензии // Аспирантский вестник Поволжья. - 2009. - № 7-8. - С. 75-79. [Chulkov VS. Osobennosti techeniya i iskhodov beremennosti u zhenshchin s razlichnymi formami arterial’noy gipertenzii. Aspirantskiy vestnik Povolzh’ya. 2009;(7-8): 75-79. (In Russ).]][Сухих Г.Т., Мурашко Л.Е. Преэклампсия. - М.: ГЭОТАР-Медиа, 2010. [Sukhikh GT, Murashko LE. Preeklampsiya. Moscow: GEOTAR-Media; 2010 (In Russ).]][Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Оbstet Gynecol. 2008;112 (2 Pt 1):359-72. doi: 10.1097/AOG.0b013e3181801d56.][Макаров О.В., Ткачева О.Н., Волкова Е.В. Преэклампсия и хроническая артериальная гипертензия у беременных: руководство для врачей. - М., 2010. - 131 с. [Makarov OV, Tkacheva ON, Volkova EV. Preeklampsiya i khronicheskaya arterial’naya gipertenziya u beremennykh: rukovodstvo dlya vrachey. Moscow; 2010. 131 p. (In Russ).].][Buhimschi CS, Norwitz ER, Funai Eet al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005;192:734-41.][Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46:1077-1085.][Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005.][Милованова А.П. Анализ причин материнской смертности: руководство для врачей. - М., 2008. - 228 с. [Milovanova AP. Analiz prichin materinskoy smertnosti: rukovodstvo dlya vrachey. Moscow; 2008. 228 p. (In Russ).]][Masuyama H, et al. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG. 2010;117(3): 314-320. doi: 10.1111/j.1471-0528.2009.02453.x.][The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens. 2007; ЕОГ-ЕОК, 2007. 25:1105-1187.]